Skip to main content
    N

    Novocure Ltd (NVCR)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $13.84
    -0.46 (-3.22%)

    Market Cap: $1.67B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(22/39)
    Avg Surprise
    -42.52%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.23
    Range$-0.31 - $-0.14
    7 analysts
    EPS Revisions
    5
    0
    7d
    5
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.33+28.2%
    60d ago$-0.24+4.1%
    30d ago$-0.24+4.1%
    7d ago$-0.24+4.1%
    Current$-0.23
    Revenue Consensus
    $182M
    Range$180M - $187M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.16
    Range$-0.29 - $0.03
    7 analysts
    Revenue Consensus
    $204M
    Range$196M - $215M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.16---
    Sep 26EST
    		-$-0.23---
    Jun 26
    Reported Jul 23
    		$-0.13N/A+56.67%Beat+63.9%
    Mar 26
    Reported Apr 30
    		$-0.62$-0.51-21.57%Miss-100.0%
    Dec 25
    Reported Feb 26
    		$-0.22$-0.41+46.34%Beat+63.9%
    Sep 25
    Reported Oct 30
    		$-0.33$-0.42+21.43%Beat-17.9%
    Jun 25
    Reported Jul 24
    		$-0.36$-0.39+7.69%Beat-16.1%
    Mar 25
    Reported Apr 24
    		$-0.31$-0.46+32.61%Beat+13.9%
    Dec 24
    Reported Feb 27
    		$-0.61$-0.36-69.44%Miss-35.6%
    Sep 24
    Reported Oct 30
    		$-0.28$-0.33+15.15%Beat+39.1%
    Jun 24
    Reported Jul 25
    		$-0.31$-0.40+22.50%Beat+42.6%
    Mar 24
    Reported May 2
    		$-0.36$-0.42+14.29%Beat+28.0%
    Dec 23
    Reported Feb 22
    		$-0.45$-0.52+13.46%Beat-25.0%
    Sep 23
    Reported Oct 26
    		$-0.46$-0.52+11.54%Beat-84.0%
    Jun 23
    Reported Jul 27
    		$-0.54$-0.50-8.00%Miss-134.8%
    Mar 23
    Reported May 4
    		$-0.50$-0.34-47.06%Miss-1150.0%
    Dec 22
    Reported Feb 23
    		$-0.36$-0.30-20.00%Miss-44.0%
    Sep 22
    Reported Oct 27
    		$-0.25$-0.26+3.85%Beat-92.3%
    Jun 22
    Reported Jul 28
    		$-0.23$-0.14-64.29%Miss-64.3%
    Mar 22
    Reported Apr 28
    		$-0.04N/A+77.78%Beat+0.0%
    Dec 21
    Reported Feb 24
    		$-0.25$-0.10-150.00%Miss-725.0%
    Sep 21
    Reported Oct 28
    		$-0.13$-0.06-116.67%Miss-244.4%
    Jun 21
    Reported Jul 29
    		$-0.14$0.01-1500.00%Miss-800.0%
    Mar 21
    Reported Apr 29
    		$-0.04$0.01-500.00%Miss-200.0%
    Dec 20
    Reported Feb 25
    		$0.04N/A-66.67%Miss+0.0%
    Sep 20
    Reported Oct 29
    		$0.09$0.04+125.00%Beat+350.0%
    Jun 20
    Reported Jul 30
    		$0.02$0.01+100.00%Beat+300.0%
    Mar 20
    Reported Apr 30
    		$0.04$0.02+100.00%Beat+130.8%
    Dec 19
    Reported Feb 27
    		$0.04$0.02+100.00%Beat+123.5%
    Sep 19
    Reported Oct 31
    		$0.02$-0.04+150.00%Beat+115.4%
    Jun 19
    Reported Jul 25
    		$-0.01N/A+83.33%Beat+94.1%
    Mar 19
    Reported May 2
    		$-0.13$-0.15+13.33%Beat+43.5%
    Dec 18
    Reported Feb 28
    		$-0.17$-0.13-30.77%Miss-41.7%
    Sep 18
    Reported Oct 25
    		$-0.13$-0.14+7.14%Beat+0.0%
    Jun 18
    Reported Jul 26
    		$-0.17$-0.16-6.25%Miss+29.2%
    Mar 18
    Reported Apr 26
    		$-0.23$-0.13-76.92%Miss-9.5%
    Dec 17
    Reported Feb 22
    		$-0.12$-0.11-9.09%Miss+53.8%
    Sep 17
    Reported Oct 26
    		$-0.13$-0.14+7.14%Beat-
    Jun 17
    Reported Jul 27
    		$-0.24$-0.22-9.09%Miss-
    Mar 17
    Reported Apr 27
    		$-0.21$-0.20-5.00%Miss-
    Dec 16
    Reported Feb 23
    		$-0.26$-0.39+33.33%Beat-

    Key Metrics

    Valuation
    P/E Ratio-10.65EV/EBITDAN/A
    Price/FCF-63.13xFCF Yield-1.58%
    Profitability
    Profit Margin-21.20%Operating Margin-5.75%
    ROE-43.20%ROIC-28.13%
    Financial Health
    Debt/Equity0.58xInterest CoverageN/A
    Current Ratio2.89xQuick Ratio2.70x
    Trading Statistics
    Beta0.99Avg Volume1.36M
    52-Week High$21.4552-Week Low$9.82

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$14.73
    SMA 20$15.50
    SMA 50$16.43
    SMA 200$14.78
    EMA 10$14.71
    EMA 20$15.25
    EMA 50$15.92
    EMA 200$15.34

    MACD

    Line: -0.64Signal: -0.51Hist: -0.13

    ADX

    ADX: 22.2+DI: 15.2-DI: 32.8

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down100.0
    PSAR$15.44

    Bollinger Bands

    Upper Band$17.33
    Lower Band$13.67
    %B Position2361%(Upper)
    Band Width0.05

    RSI (14-Day)

    Neutral
    30.8

    Momentum Oscillators

    Stoch %K17.3
    Stoch %D21.8
    Williams %R-97.0
    ROC (10d)-13.2%
    Momentum-2.11
    CCI (20d)-137.3
    MFI (14d)35.7

    Volatility Measures

    ATR (14d)$0.69(5.0%)
    StdDev (20d)0.92
    Hist Vol35.4%(Moderate)

    Volume Flow

    VWAP$13.95
    OBV6.6M
    AD Line-9.5M
    CMF (20d)-0.158

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.9x
    VWMA (20d)$15.32

    Pivot Points

    R3$15.06
    R2$14.91
    R1$14.60
    Pivot Point$14.45
    S1$14.14
    S2$13.99
    S3$13.68

    Advanced Oscillators

    TSI-27.34
    Ultimate Osc36.3
    KST-113.90

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$183.58M$174.06M$174.35M$167.20M$158.81M$154.99M$161.27M$155.09M$150.36M$138.50M$133.78M$127.32M
    Cost of Revenue$41.11M$38.93M$42.16M$44.73M$41.47M$38.52M$33.47M$35.37M$34.65M$33.69M$32.56M$32.09M
    Gross Profit$142.48M$135.13M$132.19M$122.47M$117.33M$116.47M$127.80M$119.72M$115.70M$104.81M$101.23M$95.23M
    Operating Expenses$153.04M$202.55M$172.59M$158.50M$156.85M$154.34M$191.10M$151.81M$149.28M$146.33M$152.94M$153.47M
    R&D$51.45M$58.34M$60.91M$54.03M$55.83M$53.78M$51.21M$51.88M$54.95M$51.60M$54.31M$53.62M
    SG&A$39.91M$85.85M$43.02M$45.92M$43.95M$44.77M$72.48M$40.10M$37.71M$39.53M$39.45M$41.89M
    Operating Income$-10,562,000$-67,420,000$-40,393,000$-36,021,000$-39,521,000$-37,865,000$-63,304,000$-32,092,000$-33,580,000$-41,520,000$-51,716,000$-58,245,000
    Interest Income$-1,890,000$-1,838,000$-561,000$6.00M$4.54M$7.57M$8.10M$10.51M$10.85M$9.88M$13.18M$10.02M
    Interest Expense$1.89M$1.84M$561,000$0$0$0$0$0$0$0$0$0
    Income Before Tax$-12,452,000$-69,258,000$-40,954,000$-30,022,000$-34,979,000$-30,295,000$-55,206,000$-21,585,000$-22,729,000$-31,642,000$-38,534,000$-48,222,000
    Income Tax Expense$3.21M$1.88M$-16,455,000$7.25M$5.16M$4.02M$10.72M$8.98M$10.65M$7.12M$8.54M$1.26M
    Net Income$-15,658,000$-71,138,000$-24,499,000$-37,270,000$-40,139,000$-34,319,000$-65,922,000$-30,570,000$-33,375,000$-38,760,000$-47,079,000$-49,485,000
    EBITDA$-8,848,000$-65,913,000$-39,921,000$-38,760,000$-42,537,000$-41,194,000$-66,872,000$-36,371,000$-37,576,000$-44,086,000$-56,255,000$-62,133,000
    EBIT$-10,562,000$-67,420,000$-40,393,000$-36,021,000$-39,521,000$-37,865,000$-63,304,000$-32,092,000$-33,580,000$-41,520,000$-51,716,000$-58,245,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NVCR

    Government Contracts

    Gov Obligations (TTM)
    $10.82M
    Gov Obligations / Revenue
    1.5%
    Obligations YoY
    26.4%
    Active Awards
    263
    New Awards (TTM)
    241
    Avg Remaining Term
    2.8 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26326N0625Department of Veterans AffairsDepartment of Veterans Affairs$99497Jul 21, 2026
    36C25726K0213Department of Veterans AffairsDepartment of Veterans Affairs$99497Jun 3, 2026
    36C26326N0610Department of Veterans AffairsDepartment of Veterans Affairs$99497Jul 13, 2026
    36C26326N0600Department of Veterans AffairsDepartment of Veterans Affairs$99497Jul 6, 2026
    36C26126N0522Department of Veterans AffairsDepartment of Veterans Affairs$99497Jun 22, 2026
    36C25026F0510Department of Veterans AffairsDepartment of Veterans Affairs$99497Jun 4, 2026
    36C24726N0259Department of Veterans AffairsDepartment of Veterans Affairs$99497May 22, 2026
    36C25026F0469Department of Veterans AffairsDepartment of Veterans Affairs$99497May 5, 2026
    36C25726K0119Department of Veterans AffairsDepartment of Veterans Affairs$99497Mar 13, 2026
    36C26326N0515Department of Veterans AffairsDepartment of Veterans Affairs$99497May 6, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Wall Street Zen downgrades NovoCure stock to Hold

    Wall Street Zen has downgraded NovoCure stock from Buy to Hold following the company's second-quarter revenue of $183.58 million and the recent Japanese approval of Optune Pax. Despite the approval and an increase...

    ad-hoc-news.de•10/15/26•Somewhat-Bearish

    Is NovoCure (NVCR) Undervalued Following Its Japan Approval For Optune Pax?

    NovoCure (NVCR) recently received approval in Japan for Optune Pax to treat pancreatic cancer, despite its share price having seen short-term declines but an increase year-to-date. The company is considered 71%...

    Simply Wall Street•10/14/26•Somewhat-Bullish

    Wall Street Zen downgrades Novocure stock to Hold

    Wall Street Zen has downgraded Novocure stock from Buy to Hold, citing a consensus target of USD 21.20. This comes after Novocure reported a 16% year-over-year increase in Q2 2026 revenue to USD 184.00 million and raised...

    ad-hoc-news.de•10/12/26•Somewhat-Bearish

    Did Japan Pancreatic Cancer Approval Just Shift NovoCure's (NVCR) Investment Narrative?

    Japan’s Ministry of Health, Labour and Welfare has approved NovoCure’s Optune Pax device for pancreatic cancer...

    Simply Wall Street•10/10/26•Bullish

    Did Japan Pancreatic Cancer Approval Just Shift NovoCure's (NVCR) Investment Narrative?

    Japan's Ministry of Health, Labour and Welfare has approved NovoCure's Optune Pax device for pancreatic cancer, expanding the addressable patient pool for its Tumor Treating Fields (TTFields) technology. This approval...

    Simply Wall Street•10/10/26•Bullish

    NVCR Valuation and Fair Value

    P/E
    -10.6x
    Forward P/E
    909.1x
    P/FCF
    -63.1x
    PEG
    -0.5x
    P/B
    4.7x
    See GNG's fair value

    NVCR Profitability: Margins, ROIC and FCF

    Gross margin
    76.1%
    Operating margin
    -5.8%
    Net margin
    -21.2%
    ROIC
    -28.1%
    ROE
    -43.2%
    FCF margin
    -3.6%
    FCF yield
    -1.6%

    NVCR Competitors

    CompanyTicker
    Intellia Therapeutics IncNTLA
    Azenta IncAZTA
    Dentsply Sirona IncXRAY
    Biohaven Ltd.BHVN
    Septerna, Inc. Common StockSEPN
    Nuvation Bio IncNUVB
    Personalis IncPSNL
    Omnicell IncOMCL

    Sector: Healthcare

    NVCR Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    1
    Buy
    3
    Hold
    3
    Sell
    0
    Strong Sell
    0

    NVCR Bull Case vs Bear Case

    Bull case

    • NVCR beat EPS estimates in 75.0% of its last 8 reported quarters.
    • NVCR grew quarterly revenue 15.6% year over year.

    Bear case

    • NVCR has a -21.2% net profit margin.

    NVCR Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    11.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.23
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    5 up, 1 down

    Frequently Asked Questions About NVCR

    Does NVCR pay dividends?

    Novocure Ltd (NVCR) does not currently pay a regular dividend.

    What is NVCR's market cap?

    Novocure Ltd (NVCR) has a market capitalization of $1.67B with a current stock price of $13.84.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In